S&P Futures
5,897.75 +1.25 (+0.02%) Dow Futures
43,406.00 -162.00 (-0.37%) Nasdaq Futures
20,567.25 +73.50 (+0.36%) Russell 2000 Futures
2,319.10 +5.50 (+0.24%) Crude Oil
67.37 +0.35 (+0.52%) Gold
2,598.30 +28.20 (+1.10%)
IQV Dec 2024 300.000 call
| Previous Close | 0.6000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 300.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 0.4000 - 0.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- Business Wire
IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
RESEARCH TRIANGLE PARK, N.C., November 06, 2024--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET.
TipRanksIqvia price target lowered to $265 from $280 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Iqvia (IQV) to $265 from $280 and keeps an Overweight rating on the shares. A “modest beat” in Q3 was led by better-than-expected TAS performance, but this is overshadowed by R&DS headwinds over the next twelve months, including a single large cancellation and two “mega trial delays” to 2025, the analyst tells investors in a post-earnings note. The firm views the risk/reward as attractive on the recent pullback, the analyst added. Published first
